Acumen Pharmaceuticals Inc (NAS:ABOS)

$ 2.73 -0.02 (-0.73%) Market Cap: 164.02 Mil Enterprise Value: -59.32 Mil PE Ratio: 0 PB Ratio: 0.63 GF Score: 19/100

Q1 2024 Acumen Pharmaceuticals Inc Earnings Call Transcript
May 14, 2024

$3.69 (+9.82%)

Earnings
Q4 2023 Acumen Pharmaceuticals Inc Earnings Call Transcript
Mar 26, 2024

$3.75 (-11.76%)

Earnings
Acumen Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2024
Q3 2023 Acumen Pharmaceuticals Inc Earnings Call Transcript
Nov 13, 2023

$2.03 (+6.84%)

Earnings
Acumen Pharmaceuticals Inc at UBS BioPharma Conference Transcript
Nov 09, 2023
Q2 2023 Acumen Pharmaceuticals Inc Earnings Call Transcript
Aug 08, 2023

$7

Earnings
Acumen Pharmaceuticals, Inc. - Special Call Transcript
Jul 17, 2023
Acumen Pharmaceuticals Inc at Bank of America Global Healthcare Conference Transcript
May 11, 2023
Q1 2023 Acumen Pharmaceuticals Inc Earnings Call Transcript
May 09, 2023

$5.73 (+18.14%)

Earnings
Q4 2022 Acumen Pharmaceuticals Inc Earnings Call Transcript
Mar 27, 2023

$4.21 (+7.40%)

Earnings
Q2 2022 Acumen Pharmaceuticals Inc Earnings Call Transcript
Aug 15, 2022

$5.41 (+0.19%)

Earnings
Q1 2022 Acumen Pharmaceuticals Inc Earnings Call Transcript
May 16, 2022

Earnings

Q1 2024 Acumen Pharmaceuticals Inc Earnings Call Transcript

May 14, 2024 / 12:00PM GMT

Release Date Price: $3.69 (+9.82%)

Transcript 10-Q8-K

Operator

Good day and thank you for standing by. Welcome to Acumen Pharmaceuticals First Quarter 2024 Conference Call and Webcast. (Operator Instructions) Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your first speaker today, Alex Braun, Vice President and Head of Investor Relations. Please go ahead.

Alex Braun

Acumen Pharmaceuticals Inc - Head of Investor Relations

Thanks, Norma. Good morning and welcome to the Acumen conference call to discuss our business update and financial results for the quarter ended March 31, 2024.

With me today are Dan O'Connell, our CEO; and Matt Zuga, our CFO and Chief Business Officer. Dan and Matt have some prepared remarks and then we'll open the call for questions. Joining for the Q&A session, we also have Dr. Jim Doherty, our President and Chief Development Officer; and Dr. Eric Siemers, our Chief Medical Officer.

Before we begin, we encourage listeners to go to the Investors section of the Acumen website to find our press release issued

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.